Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果，显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低

美股速递2025-12-09

Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果，研究表明，复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1116613840?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-09 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116613840","market":"us","top_or_hot":-1,"title":"Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果，显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低","media":"美股速递","content":"<p>Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果，研究表明，复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果，显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果，显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低\n</h2>\n\n<h4 class=\"meta\">\n\n2025-12-09 05:14 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果，研究表明，复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASMB","symbol_name":"Assembly Biosciences Inc.","start_time":0,"source_url":"","article_id":"1116613840","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116613840","pubTimestamp":1765228452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果，研究表明，复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ASMB":"Assembly Biosciences Inc.","BK4139":"生物科技"},"translate_title":"Assembly Biosciences releases positive interim results from a Phase 1B clinical study of long-acting helicase-primase inhibitor drug candidates Abi-1179 and Abi-5366, showing reduced viral excretion rates and virus-confirmed genital damage rates in recurrent genital herpes simplex","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1},"content_text":"Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果，研究表明，复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116613840","isCrawlerRequest":true}